Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Lymphatic Leukemia
100%
Rituximab
23%
Remission
22%
Fludarabine
22%
Venetoclax
18%
Diseases
17%
Ibrutinib
16%
Acute Myeloid Leukemia
15%
Overall Survival
15%
Cyclophosphamide
15%
Acute Lymphoblastic Leukemia
13%
Leukemia
13%
Minimal Residual Disease
11%
Progression Free Survival
11%
Chemotherapy
10%
Myelodysplastic Syndrome
10%
Cytarabine
9%
Chronic Myeloid Leukemia
9%
Lymphocytic Lymphoma
8%
Philadelphia 1 Chromosome
8%
Bruton Tyrosine Kinase Inhibitor
8%
Malignant Neoplasm
7%
Adverse Event
7%
Alemtuzumab
7%
Imatinib
6%
Protein Tyrosine Kinase Inhibitor
6%
Clinical Trial
6%
Lenalidomide
5%
Chimeric Antigen Receptor
5%
Survival Rate
5%
Acalabrutinib
5%
Keyphrases
Chronic Lymphocytic Leukemia
97%
Relapsed or Refractory
19%
Rituximab
18%
Venetoclax
18%
Ibrutinib
17%
Chronic Lymphocytic Leukemia Cells
15%
Complete Remission
15%
Fludarabine
15%
Cyclophosphamide
12%
Acute Myeloid Leukemia
12%
Chronic Myeloid Leukemia
12%
Overall Survival
11%
Phase II Study
11%
Minimal Residual Disease
10%
Chemoimmunotherapy
9%
Richter Transformation
8%
Progression-free Survival
8%
Leukemia Patients
7%
Bruton Tyrosine Kinase Inhibitor
7%
Acute Lymphoblastic Leukemia
7%
Relapsed or Refractory Acute Myeloid Leukemia
6%
Leukemia
6%
Adverse Events
6%
Overall Response Rate
6%
Hematological Malignancies
6%
Phase II Trial
5%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
5%
Lenalidomide
5%
Newly Diagnosed
5%
Myelodysplastic Syndrome
5%
Complete Response
5%
Alemtuzumab
5%
Clinical Trials
5%
Tyrosine Kinase Inhibitor
5%
Cytarabine
5%
Acalabrutinib
5%
Medicine and Dentistry
B-Cell Chronic Lymphocytic Leukemia
84%
Ibrutinib
18%
Overall Survival
16%
Venetoclax
13%
Rituximab
13%
Diseases
13%
Leukemia Cell
13%
Minimal Residual Disease
12%
Acute Myeloid Leukemia
12%
Lymphocytic Lymphoma
11%
Chronic Myelogenous Leukemia
11%
Acute Lymphoblastic Leukemia
11%
Progression Free Survival
10%
Fludarabine
9%
B Cell
8%
Bruton Tyrosine Kinase Inhibitor
8%
Cancer
8%
Cyclophosphamide
7%
Chronic Lymphocytic Leukemia
7%
Leukemia
7%
Tyrosine-Kinase Inhibitor
7%
Richter's Transformation
7%
Adverse Event
7%
Philadelphia 1 Chromosome
7%
Malignant Neoplasm
7%
Chemoimmunotherapy
6%
Myelodysplastic Syndrome
6%
T Cell
6%
Clinical Trial
5%
Imatinib
5%
B Lymphocyte Receptor
5%